These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2007-002906-23 A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease 2009-07-02 due-trials
Reported results 2007-003035-22 A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease 2018-05-30 due-trials
Not reported 2007-003051-36 A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease 2009-12-22 due-trials
Reported results 2010-020008-31 A Single center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer’s Disease 2016-10-27 due-trials
Reported results 2016-001127-32 A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer’s Disease 2018-02-16 due-trials
Reported results 2016-001128-78 A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects with Alzheimer’s Disease 2019-02-25 due-trials
Reported results 2016-003434-24 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia 2019-06-25 due-trials
Ongoing 2016-003435-38 A 52-Week, Open-Label, Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia not-yet-due
Reported results 2016-003436-20 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia 2019-10-28 due-trials
Completed, but no date 2016-003437-18 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (Enhance-2) Eine randomisierte, doppe... bad-data
Not reported 2016-003512-12 An Open-Label Extension Study to Examine the Safety and Tolerability of Pimavanserin in the Treatment of Parkinson’s Disease Psychosis 2022-12-14 due-trials
Listed as ongoing, but also has a completion date and reported results 2017-002227-13 A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis 2020-07-16 bad-data
Not reported 2017-003536-36 A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative D... 2022-05-06 due-trials
Completed, report not yet due 2017-004439-36 A 52-Week Open-Label Extension Study of Pimavanserin in Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease 52-седмично, открито разширено изпитване на pi... 2023-05-05 not-yet-due
Reported results 2018-001064-30 A Phase 1, Open Label, Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Pimavanserin in Adolescents with Psychiatric Disorders 2019-09-26 due-trials
Reported results Terminated 2018-003251-37 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Resp... 2020-05-29 due-trials
Listed as ongoing, but also has a completion date and reported results 2018-003252-20 A 52-Week Open-Label Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment 2021-02-28 bad-data
Ongoing 2019-003343-29 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE 2) not-yet-due
Other 2021-005387-22 A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder not-yet-due
Other 2021-005388-32 A 52-Week Open-Label Extension Study of Pimavanserin in Children and Adolescents with Irritability Associated with Autism Spectrum Disorder (ASD) Studio di estensione in aperto di 52 settimane su ... not-yet-due